Posttreatment Infarct Volumes when Compared with 24-Hour and 90-Day Clinical Outcomes: Insights from the REVASCAT Randomized Controlled Trial

References

1. 1.↵
   2. Berkhemer OA,
   3. Fransen PS,
   4. Beumer D, et al

   . A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11–20 doi:10.1056/NEJMoa1411587 pmid:25517348

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Goyal M,
   3. Demchuk AM,
   4. Menon BK, et al

   ; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019–30 doi:10.1056/NEJMoa1414905 pmid:25671798

   CrossRefPubMed
3. 3.↵
   2. Campbell BC,
   3. Mitchell PJ,
   4. Kleinig TJ, et al

   ; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372:1009–18 doi:10.1056/NEJMoa1414792 pmid:25671797

   CrossRefPubMed
4. 4.↵
   2. Saver JL,
   3. Goyal M,
   4. Bonafe A, et al

   ; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015;372:2285–95 doi:10.1056/NEJMoa1415061 pmid:25882376

   CrossRefPubMed
5. 5.↵
   2. Jovin TG,
   3. Chamorro A,
   4. Cobo E, et al

   ; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2296–306 doi:10.1056/NEJMoa1503780 pmid:25882510

   CrossRefPubMed
6. 6.↵
   2. Macrae IM

   . Preclinical stroke research: advantages and disadvantages of the most common rodent models of focal ischaemia. Br J Pharmacol 2011;164:1062–78 doi:10.1111/j.1476-5381.2011.01398.x pmid:21457227

   CrossRefPubMed
7. 7.↵
   2. Duncan PW,
   3. Jorgensen HS,
   4. Wade DT

   . Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke 2000;31:1429–38 doi:10.1161/01.STR.31.6.1429 pmid:10835468

   Abstract/FREE Full Text
8. 8.↵
   2. Quinn TJ,
   3. Dawson J,
   4. Walters MR, et al

   . Functional outcome measures in contemporary stroke trials. Int J Stroke 2009;4:200–05 pmid:19659822

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Banks JL,
   3. Marotta CA

   . Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007;38:1091–96 doi:10.1161/01.STR.0000258355.23810.c6 pmid:17272767

   Abstract/FREE Full Text
10. 10.↵
    2. Thijs VN,
    3. Lansberg MG,
    4. Beaulieu C, et al

    . Is early ischemic lesion volume on diffusion-weighted imaging an independent predictor of stroke outcome? A multivariable analysis. Stroke 2000;31:2597–602 doi:10.1161/01.STR.31.11.2597 pmid:11062281

    Abstract/FREE Full Text
11. 11.↵
    2. Wardlaw JM,
    3. Keir SL,
    4. Bastin ME, et al

    . Is diffusion imaging appearance an independent predictor of outcome after ischemic stroke? Neurology 2002;59:1381–87 doi:10.1212/01.WNL.0000032495.71720.C3 pmid:12427888

    CrossRefPubMed
12. 12.↵
    2. Saver JL,
    3. Johnston KC,
    4. Homer D, et al

    . Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials: the RANTTAS investigators. Stroke 1999;30:293–98 doi:10.1161/01.STR.30.2.293 pmid:9933262

    Abstract/FREE Full Text
13. 13.↵
    2. Kimura K,
    3. Sakamoto Y,
    4. Iguchi Y, et al.

    , Serial changes in ischemic lesion volume and neurological recovery after t-PA therapy. J Neurol Sci 2011;304:35–39 doi:10.1016/j.jns.2011.02.024 pmid:21397255

    CrossRefPubMed
14. 14.↵
    2. Rha JH,
    3. Saver JL

    . The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007;38:967–73 doi:10.1161/01.STR.0000258112.14918.24 pmid:17272772

    Abstract/FREE Full Text
15. 15.↵
    2. Al-Ajlan FS,
    3. Goyal M,
    4. Demchuk AM, et al

    ; ESCAPE Trial Investigators. Intra-arterial therapy and post-treatment infarct volumes: insights from the ESCAPE randomized controlled trial. Stroke 2016;47:777–81 doi:10.1161/STROKEAHA.115.012424 pmid:26892284

    Abstract/FREE Full Text
16. 16.↵
    2. Saver JL

    . Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007;38:3055–62 doi:10.1161/STROKEAHA.107.488536 pmid:17916765

    Abstract/FREE Full Text
17. 17.↵
    2. Kosior JC,
    3. Idris S,
    4. Dowlatshahi D, et al

    ; PREDICT/Sunnybrook CTA ICH study investigators. Quantomo: validation of a computer-assisted methodology for the volumetric analysis of intracerebral haemorrhage. Int J Stroke 2011;6:302–05 doi:10.1111/j.1747-4949.2010.00579.x pmid:21609412

    CrossRefPubMed
18. 18.↵
    2. Zaidat OO,
    3. Yoo AJ,
    4. Khatri P, et al

    ; STIR Thrombolysis in Cerebral Infarction (TICI) Task Force. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke 2013;44:2650–63 doi:10.1161/STROKEAHA.113.001972 pmid:23920012

    FREE Full Text
19. 19.↵
    2. Baron RM,
    3. Kenny DA

    . The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173–82 doi:10.1037/0022-3514.51.6.1173 pmid:3806354

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Sajobi TT,
    3. Menon BK,
    4. Wang M, et al

    ; ESCAPE Trial Investigators. Early trajectory of stroke severity predicts long-term functional outcomes in ischemic stroke subjects: results from the ESCAPE Trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). Stroke 2017;48:105–10 doi:10.1161/STROKEAHA.116.014456 pmid:27924049

    Abstract/FREE Full Text
21. 21.↵
    2. Bulterijs S,
    3. Hull RS,
    4. Björk VC et al

    . It is time to classify biological aging as a disease. Front Genet 2015;6:205 doi:10.3389/fgene.2015.00205 pmid:26150825

    CrossRefPubMed